Literature DB >> 3108460

Synergistic antiproliferative effect of recombinant alpha-interferons with recombinant gamma-interferon.

H R Hubbell, J A Craft, P J Leibowitz, D H Gillespie.   

Abstract

Two human tumor cell lines were studied for their response to the antiproliferative effect of recombinant human interferons (IFNs) alpha 2, alpha 4, a hybrid alpha (delta 4 alpha 2 Bgl II alpha 1), and gamma, individually and in combination. Natural human alpha-IFN was used as a reference point for all experiments. RT4 (bladder carcinoma) cells were overall more sensitive to the antiproliferative effects of the IFNs than A2182 (lung adenocarcinoma) cells. Three-way analysis of variance indicated that the relative effectiveness of the alpha-IFNs was alpha 2 less than alpha 4 less than hybrid alpha less than natural alpha-IFN. On an international reference unit per milliliter basis, gamma-IFN was 50- and 75-fold more effective than natural alpha-IFN and hybrid alpha-IFN in RT4 cells and 5.6-, 12.1-, and 14.9-fold more effective than alpha 4-, hybrid alpha-, and natural alpha-IFN in A2182 cells. In contrast, when recalculated on a nanogram per milliliter basis, gamma-IFN was only threefold more effective than the hybrid alpha-IFN in RT4 and approximately twofold less effective than alpha 4 and the hybrid alpha in A2182. Combinations of alpha-IFNs gave additive or antagonistic effects. When any of the alpha-IFNs were combined with the gamma-IFN, however, a synergistic antiproliferative effect was seen. The magnitude of the synergy was dependent upon the concentration of gamma-IFN used and the type of alpha-IFN in the combination. Antagonistic effects were seen at the lowest gamma-IFN concentration studied (0.2 IRU/ml). Synergy also varied according to the potency of the alpha-IFN used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108460

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  6 in total

Review 1.  The cellular receptor of the alpha-beta interferons.

Authors:  K E Mogensen; G Uzé; P Eid
Journal:  Experientia       Date:  1989-06-15

2.  Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.

Authors:  P H de Mulder; F M Debruyne; M P Franssen; A D Geboers; S Strijk; A G Reintjes; W H Doesburg; O Damsma
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.

Authors:  G M Graham; L Guarini; T A Moulton; S Datta; S Ferrone; P Giacomini; R S Kerbel; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Sensitivities of human glioma cell lines to interferons and double-stranded RNAs individually and in synergistic combinations.

Authors:  R S Dick; H R Hubbell
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

5.  Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3.

Authors:  D E Levy; D J Lew; T Decker; D S Kessler; J E Darnell
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

6.  EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.

Authors:  P H De Mulder; G Oosterhof; C Bouffioux; A T van Oosterom; K Vermeylen; R Sylvester
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.